BioBridgeX
Log inCompare quotes
Modality

Natural Product / Botanical CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Developing a Natural Product or Botanical drug means turning a plant, fungal, or marine-derived material into a controlled, reproducible therapeutic. It needs CRO and CDMO work across botanical sourcing and authentication, extraction and fractionation, isolation and structure elucidation, chemical fingerprinting, GMP manufacturing, and analytical characterization of complex mixtures. On BioBridgeX you compare qualified vendors as neutral vendor of record, free for buyers, under one contract.

Natural Product / Botanical CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Natural Product / Botanical CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Natural Product / Botanical drug?

A natural product program starts with material, not a single molecule, and that is the whole challenge. Your starting point is a plant, a fungus, a marine organism, or a fermentation broth, and the active principle may be one isolated compound or, in the botanical drug case, a defined multi-component mixture where the activity lives in the combination rather than any one peak on a chromatogram. The FDA recognizes this through its Botanical Drug Development guidance, which leans on totality-of-the-evidence and consistent manufacturing instead of demanding you pin everything on one purified molecule. So before chemistry even begins you have to decide what your drug actually is: a single natural product entity, a semi-synthetic derivative, or a characterized botanical extract.

On the discovery and preclinical side the work looks familiar but carries natural-product baggage. You need isolation and purification (often bioassay-guided fractionation), structure elucidation by NMR and high-resolution mass spec, dereplication so you do not spend six months rediscovering a known compound, and supply chain thinking from day one because the molecule that cured the assay may exist at milligrams per kilogram of biomass. Total synthesis or semi-synthesis is frequently the only realistic route to clinical quantities, and that decision belongs early, not after a Phase 1 supply crisis. Preclinical pharmacology, DMPK, and tox then run much like any small-molecule program, with the caveat that a complex mixture complicates exposure and reproducibility.

CMC and manufacturing are where specialist Natural Product / Botanical CDMOs earn their keep and where generalists struggle. The core problem is batch-to-batch consistency from a biological raw material whose composition shifts with species, geography, harvest season, and growing conditions. That forces botanical raw material authentication (taxonomic and DNA-based identity), control of the agricultural or collection source, validated extraction and fractionation, and chemical fingerprinting by HPLC, UPLC, or LC-MS to prove that lot 40 matches lot 1. A generalist small-molecule CDMO that thinks in terms of one API and one impurity profile is not set up for a chromatographic fingerprint, marker-compound quantitation, or the heavy-metal, pesticide, aflatoxin, and microbial testing that plant material demands. The two FDA-approved botanical drugs, Veregen (sinecatechins) and Mytesi (crofelemer), got there on exactly this kind of manufacturing rigor, and that is the bar a serious program plans against.

How do you choose a CRO or CDMO for Natural Product / Botanical?

Score two or three vendors against one written scope rather than collecting quotes that measure different things, and weight modality fit above headline price. A lab that has actually taken a botanical extract or a natural-product API through characterization and into GMP supply is worth far more than a cheaper generalist who will learn on your program. Use this checklist when you compare candidates.

  • Relevant platform and track record: ask for completed natural-product or botanical programs, not capability slides. Have they done bioassay-guided fractionation, dereplication, isolation and structure elucidation, or a defined botanical extract before, and did any reach IND or NDA. The two approved US botanical drugs prove this is doable, but the experience base is thin, so real references matter.
  • GxP and analytical capability for this modality: confirm the analytical toolkit fits a complex mixture, not a single API. You want validated chemical fingerprinting (HPLC, UPLC, LC-MS), marker-compound quantitation, NMR and high-resolution MS for structure work, and the contaminant panel plant material requires (heavy metals, residual pesticides, aflatoxins, residual solvents, microbial limits). Check GMP status for any clinical or commercial supply and GLP for pivotal safety studies.
  • Raw material control and sourcing: this is the make-or-break for botanicals. Ask how they authenticate botanical identity (taxonomic and DNA barcoding), how they control the agricultural or wild-collection source, and how they handle seasonal and geographic variability so batches stay within spec. A vendor without an answer here cannot deliver consistency, and consistency is the regulatory story.
  • Extraction, isolation, and scale-up capacity: confirm they can run validated extraction and fractionation and then scale it, and ask candidly whether your supply path is sustainable biomass or whether semi-synthesis or total synthesis is the realistic route to clinical quantities. Pin down real capacity and a milestone timeline, since botanical material lead times and harvest cycles bite differently than ordering a reagent.
  • Regulatory experience for botanical drugs: prefer a partner who knows the FDA Botanical Drug Development pathway and the totality-of-the-evidence framing, can author the chemistry and consistency sections that pathway demands, and understands where a botanical drug diverges from a dietary supplement or NDI submission. The regulatory intent shapes the whole CMC design, so this is not a bolt-on.
  • IP and freedom to operate: natural-product IP is its own minefield, since the natural compound itself may not be patentable in the form you found it. Confirm how the vendor handles composition-of-matter versus method, semi-synthetic derivatives, extract and formulation claims, and the chain of custody and benefit-sharing obligations (Nagoya Protocol) that can attach to source material collected abroad.

Frequently asked questions

What is a botanical drug and how is it different from a dietary supplement?
A botanical drug is a product made from plant material (or algae, fungi, or their combinations) that is intended to diagnose, treat, or prevent disease, and it goes through the full FDA drug approval process under CDER. A dietary supplement is regulated as a food and cannot make disease-treatment claims. The FDA's Botanical Drug Development guidance lays out a specific path for botanical drugs that allows a defined multi-component mixture to be the active, provided you can prove the product is consistently manufactured and supported by adequate evidence. Veregen and Mytesi are the two botanical drugs approved through this pathway in the US, which is why the experience base among CROs and CDMOs is real but narrow.
Why is batch-to-batch consistency the hardest part of a botanical program?
Because your raw material is biological, its composition shifts with species, growing region, harvest season, soil, and processing. Unlike a synthetic API with one defined structure, a botanical extract is a mixture of dozens or hundreds of constituents, and you have to show that every commercial lot matches the lots used in your clinical trials. That is done through controlled sourcing, botanical authentication, validated extraction, and chemical fingerprinting (HPLC, UPLC, or LC-MS) plus marker-compound quantitation. A CDMO that cannot fingerprint a mixture and hold it to spec cannot carry the program, and the FDA reviews this consistency story closely.
Do I need to isolate a single compound or can the whole extract be the drug?
Both routes exist and the decision shapes everything downstream. If one natural product is the active, you isolate it, elucidate its structure, and develop it like a small molecule, often relying on semi-synthesis or total synthesis to reach clinical quantities. If the activity lives in the combination, you can pursue a botanical drug where a characterized multi-component extract is the active, which the FDA pathway explicitly allows. Make this call early, because it determines your CMC strategy, your analytical methods, your supply plan, and your IP position. Bioassay-guided fractionation and dereplication during discovery usually inform the answer.
How do I get enough material for clinical trials from a natural source?
Supply is a real risk and it belongs in the plan from day one. Many natural products occur at very low concentration in their source organism, so harvesting biomass does not scale to clinical or commercial demand. Common answers are cultivation or controlled wild collection for botanical extracts, fermentation for microbial natural products, and semi-synthesis or total synthesis for isolated single-compound drugs. Ask any CDMO candidate directly how they would secure sustainable supply for your specific molecule, and factor harvest cycles and biomass lead times into the timeline, since they behave nothing like ordering a synthetic intermediate.
What contaminant and safety testing does plant-derived material require?
Plant and natural material carries contamination risks a purely synthetic route does not, so the analytical panel is broader. Expect heavy-metals testing, residual pesticide screening, aflatoxin and mycotoxin testing, residual solvents from extraction, and microbial limits, on top of identity and assay. Botanical identity itself has to be authenticated taxonomically and increasingly by DNA barcoding to rule out adulteration or substitution. Confirm your CDMO runs this full panel under GMP and that pivotal safety studies are run under GLP, because gaps here surface late and are expensive to fix.
How does sourcing Natural Product / Botanical services through BioBridgeX work?
BioBridgeX is a neutral marketplace and vendor of record for outsourced drug development. It runs no lab work itself. You compare qualified CRO and CDMO vendors across the workstreams a natural-product program needs (sourcing and authentication, extraction and fractionation, isolation and structure elucidation, fingerprinting and characterization, GLP safety, and GMP supply) and run the ones you pick under one contract, one PO, and one invoice instead of negotiating each lab separately. It is free for buyers, and vendors pay a flat 2% on a pay-when-paid basis, so there is no incentive to steer you toward a pricier lab. Vendor profiles are openly discoverable so you can size up fit before any sales call, and because coverage spans all indications and modalities you can keep the same coordinator as your candidate moves from discovery into GMP manufacturing.

Source Natural Product / Botanical work with one contract

Compare transparent quotes from qualified Natural Product / Botanical CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes